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erythematosusAbstract Aim of the work: This study was conducted to compare the HLA-DQB1*06 allele
frequency among Egyptian SLE patients and controls. The association of that allele with clinical
features and distinct autoantibody proﬁles in SLE patients was also assessed.
Patients and methods: This study included 48 consecutive Egyptian SLE patients and 49 age and
sex matched unrelated healthy Egyptian subjects as a control group. All patients underwent full
history taking, thorough clinical examination, SLE cumulative organ damage was scored using
the Systemic Lupus International Collaborating Clinics (SLICC) damage index. Routine laboratory
investigations were done as well Genomic DNA ampliﬁcation by polymerase chain reaction with
sequence-speciﬁc primers technique (PCR-SSP) to detect HLA DQB1*6.
Results: HLA-DQB1*06 was signiﬁcantly more frequent among the SLE patients. Our results
showed HLA-DQB1*06 to be associated with SLE (39.6% in patients and 8.2% in controls,
OR = 7.23; 95% CI = 2.22–23.6; P= .00). We found no association with the clinical ﬁndings
or antibodies found in our patients apart from a signiﬁcant negative association with vasculitis.
Conclusion: The current work suggests that DQB1*06 allele is a susceptibility allele in Egyptian
patients with SLE but is not related to the clinical presentation or laboratory tests of SLE. To our
knowledge this is the ﬁrst study of the frequency of DQB1*06 alleles in Egyptian SLE patients.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease with variable clinical presentation.
SLE can affect all organs and the involvement of major
organs can be life threatening. The exact pathological mech-
anisms of SLE remain elusive, and the etiology of SLE is
known to be multifactorial [1]. The disease is due to the
interaction between genetic, immunologic, endocrine and
environmental factors [2]. Therefore, gene–gene and
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disease complicate the interpretation of the data generated
from family-based linkage and association studies [3]. Recent
genome wide association studies have identiﬁed many candi-
date genes for lupus susceptibility [4].
To date, the strongest associations of genetic factors with
SLE are with variants located in the major histocompatibility
complex (MHC) on the short arm of chromosome 6 that con-
tains hundreds of genes, many of them with immune-related
functions [5,6]. The MHC class II region is the densest area
of the genome for disease associations [7]. The MHC can be
divided into three regions, termed classes I, II, and III. Classi-
cal classes I and II loci encode the human leukocyte antigen
(HLA) proteins involved in antigen presentation to T cells
[6]. The centromeric Class II region contains the highly poly-
morphic HLA-DR, -DQ and -DP genes. Class II molecules
are heterodimers consisting of an alpha (DQA) and a beta
chain (DQB), both anchored to the membrane, which play a
central role in the immune system by presenting peptides
derived from extracellular proteins. These molecules are
expressed at high levels on antigen-presenting cells, such as
dendritic cells and B cells and display peptides for CD4 helper
T cells. These genes have been found to consistently associate
with SLE in several populations [8,9]. HLA-DQ antigen is an
HLA class II molecule encoded by the 2 sets of DQ genes,
DQA1 and DQB1. Although both the DQA1 and DQB1 genes
are polymorphic, DQB1 gene is more polymorphic and is the
major determinant of the DQ antigen [10]. An association
between HLA-DQ6 and SLE patients among some races in
the Middle East has been reported.
The degree of association between SLE and speciﬁc genes
of the MHC region varies considerably from one population
group to another [11,12]. Understanding the genetic basis
may predict high-risk patients who carry one or more genetic
susceptibility factors among the general population or within
families. In addition, if we know the environmental factors
or triggering factors of the disease, the identiﬁcation of indi-
viduals with high-risk genetic background may prevent or at
least delay the development of disease by the environmental
control and genetic counseling of the high-risk family members
as well as enhance our understanding of disease pathogenesis
[13]. In the future, knowledge of an individual’s genotype
may help us tailor the most appropriate treatment for that
SLE individual [3].
Aim of the work: We conducted this study to compare the
HLA-DQB1*06 allele frequency among SLE patients and con-
trols and analyze its contribution to the susceptibility to SLE
in Egyptians. In addition, we assessed the association of that
allele with clinical features of the disease and distinct autoan-
tibody proﬁles in SLE patients.Table 1 Nuclotide sequences, length, Tm and speciﬁcities of the PC
by the PCR-SSP technique.
Primer mix2 Primer sequence Length
DQ6 Forward Sequence
50GGGACGGAGCGCGTGCGTTA30 20 mer
50GGGACGGAGCGCGTGCGTCT30 20 mer
DQ6 Reverse Sequence
50CTGCAAGATCCCGCGGAACG30 20 mer
50TGCAGGATCCCGCGGTACC30 19 mer2. Patients and methods
This study included 48 consecutive Egyptian SLE patients
recruited from the Departments of Rheumatology and Reha-
bilitation Cairo and Ain Shams Universities, Egypt. Diagnosis
of SLE was established according to the American College of
Rheumatology (ACR) revised Criteria for diagnosis of SLE
[14]. The study also included 49 age and sex matched unrelated
healthy Egyptian subjects as a control group. The nature of the
present study and a written informative consent was obtained
from all patients, which was approved by the local Ethics
Committee. Exclusion criteria included non-Egyptian patients,
related SLE patients, and patients with other autoimmune dis-
ease or overlap syndrome.
2.1. Patient evaluation
SLE patients were subjected to thorough history taking, gen-
eral and local examination. The SLE cumulative organ dam-
age was scored using the Systemic Lupus International
Collaborating Clinics (SLICC) damage index [15]. Laboratory
investigations included full blood picture, erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), serum creatinine,
simple urine analysis and estimation of 24 h urinary protein,
urine protein/creatinine ratio (P/C ratio), alanine transaminase
(ALT), aspartate transaminase (AST), C3, C4, antinuclear
antibody (ANA) and anti-double stranded deoxyribonucleic
acid (anti-dsDNA). Blood and urine samples were collected
on the same day. Radiological studies including plain X-ray
of the chest, affected joints and echocardiography when
needed.
2.2. Determination of HLA-DQB1*06 gene
DNA was extracted from white blood cells of 2 mL of k3
EDTA samples by column extraction method using QIA
amp DNA blood mini kit-Qiagen (from HOFFmann-la Roche
AG). HLA-DQB1Gene was ampliﬁed and detected by
polymerase chain reaction with sequence speciﬁc primers
(PCR-SSP) technique. Each PCR reaction mixture contained
four group speciﬁc DQB1 primers as well as the internal
control primer pair, to avoid false-negative typing results due
to primer competition. The internal positive control primers
were included in a fourfold lower concentration than the allele
and group-speciﬁc primers. Their sequences were (forward pri-
mer 50GCCTTCCCAACCATTCCCTTA30), (reverse primer
50TCACGGATTTCTGTTGTGTTTC30) (Table 1). Each
10 lL PCR reaction consisted of 100 ng genomic DNA, PCR
buffer 50 mM KCl 1.5 mM1 MgCl2 10 mH
1 Tris–Cl,R primers used for identiﬁcation of the allelic series of DQ series
Tm Size of PCR product Ampliﬁed speciﬁcities
218/219 bp DQB1
68 C
70 C
601–609
66 C
64 C
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0:001
% ðw=vÞgelatinÞ, 200 lm each of d ATP, d GTP and d
TTP 0.40 lm of the allele and group. Speciﬁc DQB1 primers,
0.10 lm of the control primers and 0.25–0.40 units of Ampli
Taq (perkin–Elmer cetus corporation), 5% (v/v) glycerol
(redistilled) [16,17] and cresol red, sodium salt ð100 l mL1Þ.
PCR ampliﬁcation was carried out in a thermal cycler. After
an in initial denaturation at 94 C for 2 min. DNAs were
ampliﬁed by 30 ampliﬁcation cycles. The ﬁrst 10 cycles
consisted of denaturation at 94 C for 10 s and a combined
annealing-extension step at 66 C for 60 s, the 20 following
cycles consisted of denaturation at 94 C for 10 s, annealing
at 61 C for 50 s and extension at 72 C for 30 s. The same
PCR parameters were used for conventionally as well as for
rapidly extracted DNAs.
The whole PCR reactions were directly electrophoresed in
2% ME agarose gels prestained with eithidium bromide
ð0:25 lg mL1 geLÞ the gels were run for 15 min at 10 cm1
in 0.5· TBE buffer (89 mM Tris base, 89 mM boric acid,
2 mM EDTA, pH 8) and visualized under UV illumination
(Fig. 1).
Statistical methods: IBM SPSS statistics (V. 22.0, IBM
Corp., USA, 2013) was used for data analysis. Data were
expressed as Median & Percentiles for quantitative non-
parametric measures and in addition, both number and per-
centage for categorized data.
The following tests were done:
1. Chi-square test to study the association between each of the
2 variables or comparison between 2 independent groups as
regards the categorized data. The probability of error at
0.05 was considered signiﬁcant, while at 0.01 and 0.001
are highly signiﬁcant.
2. Calculated Relative Risk Assessments (Relative Risk Ratio
or RRR) that measure how many times the risk was present
among diseased individuals as that among non-diseased
ones. They were calculated as absolute ﬁgures and as a
standard error of estimate (95P).Figure 1 HLA-DQ6 (601–609) PCR products as an example of
eight PXR mix for typing of seven HLA DQBI allele group.
Positive subjects show 218,219 bp bands and negative subjects
show no bands at 218,219 bp. Lane 1: 100 bp Ladder. Lanes: 2, 5,
6, 7, 8, 9 HLA DQ6 positive subject. Lanes: 3, 4 negative subject.3. Results
This study included 48 SLE patients; their ages ranged from 18
to 51 with a mean of 31.37 ± 8.85 years. Their disease
duration ranged from 0.5 to 35 years with a mean of
10.96 ± 8.64 years. Our patients were 42 females and 6 males
with a female to male ratio of 7:1. The study also included 49
age and sex matched healthy subjects that served as a control
group. Clinical presentation and laboratory data of SLE
patients are shown in Table 2. The SLICC score in our patients
ranged from 0 to 2.
HLA-DQB1*06 was signiﬁcantly increased in patients ver-
sus controls denoting a positive association between it and
SLE in Egyptian patients (Table 3). It failed to show any asso-
ciation with the clinical ﬁndings or antibodies found in our
patients apart from a signiﬁcant negative association with vas-
culitis (Table 4). The age of onset of SLE did not show signif-
icant difference among patients positive for HLA-DQB1*06
and patients lacking this allele (P> 0.05). 73.10% of the
HLA-DQB1*06 negative patients had a SLICC score of 0,
23.10% had a score of 1 while 3.80% had a score of 2. The
HLA-DQB1*06 positive patients showed 61.10% with a
SLICC score of 0, 38.90% with a score of 1 while none of
the patients scored 2. The presence of the allele did not associ-
ate with the SLICC score (OR = 1.34, P= 0.403).
4. Discussion
Systemic lupus erythematosus (SLE) is a serious prototype
autoimmune disease characterized by chronic inﬂammation,
autoantibody production and multi-organ damage [9]. Genetic
susceptibility to SLE is well established. MHC is the strongest
genetic factor for SLE. Altered frequencies of human leuko-
cyte antigen (HLA) alleles are known to be associated withTable 2 Clinical presentation and laboratory data of the
systemic lupus erythematosus (SLE) patients.
Clinical presentation Number (%)
Mucucutaneous manifestations 37 (77.1)
Musculoskeletal manifestations 37 (77.1)
Serositis 22 (45.8)
Cardiac aﬀection 3 (6.25)
Pulmonary aﬀection 5 (10.4)
CNS aﬀection 15 (31.25)
GIT aﬀection 5 (10.4)
Hematologic aﬀection 25 (52.1)
History of DVT 9 (18.75)
Renal aﬀection 29 (60.4)
Raynaud’s phenomenon 4 (8.3)
Vasculitis 11 (22.9)
Laboratory data
Positive ANA 42 (87.5)
Positive anti dsDNA 37 (77.1)
Lupus Anti Coagulant 12 (25)
Positive Antiphospholipid 12 (25)
Positive anti cardiolipin 14 (29.2)
CNS: central nervous system, GIT: gastrointestinal, DVT: deep
venous thrombosis, ANA: antinuclear antibody, dsDNA: double
stranded deoxyribonucleic acid.
Table 4 HLA-DQB1*06 genotype frequency in SLE patients relative to SLE phenotype.
Manifestation HLA-DQB1*06 in SLE patients (%) OR 95% CI P Sig
Negative Positive
Mucocutaneous Neg. 25 11.1 2.7 0.49–14.6 0.25 NS
Pos. 75 88.9
Musculoskeletal Neg. 14.3 27.8 0.43 0.09–1.9 0.26 NS
Pos. 85.7 72.2
Serositis Neg. 60.7 38.9 2.43 0.72–8.18 0.15 NS
Pos. 39.3 61.1
Cardiac Neg. 92.9 94.4 0.77 0.06–9.11 0.83 NS
Pos. 7.1 5.6
Pulmonary Neg. 89.3 88.9 1.04 0.16–6.94 0.97 NS
Pos. 10.7 11.1
CNS Neg. 64.3 72.2 0.69 0.19–2.51 0.58 NS
Pos. 35.7 27.8
GIT Neg. 89.3 88.9 1.04 0.16–6.94 0.97 NS
Pos. 10.7 11.1
Hematologic Neg. 53.6 33.3 2.31 0.68–7.89 0.18 NS
Pos. 46.4 66.7
History of DVT Neg. 85.7 72.2 2.31 0.53–10.1 0.26 NS
Pos. 14.3 27.8
Renal Neg. 39.3 33.3 1.29 0.38–4.4 0.68 NS
Pos. 60.7 66.7
Raynaud’s Neg. 85.7 100 – – 0.09 NS
Pos. 14.3 0
Vasculitis Neg. 63 94.4 0.09 0.01–0.78 0.02 S
Pos. 37 5.6
Positive ANA Neg. 14.3 0 – – 0.09 NS
Pos. 85.7 100
Positive antidsDNA Neg. 25 11.1 2.7 0.49–14.6 0.25 NS
Pos. 75 88.9
LA Neg. 75 70.6 1.15 0.30–4.41 0.75 NS
Pos. 25 29.4
Positive APL Neg. 75 70.6 1.15 0.30–4.41 0.75 NS
Pos. 25 29.4
Positive ACL Neg. 75 58.8 1.91 0.53–6.84 0.26 NS
Pos. 25 41.2
LA: lupus anticoagulant, APL: antiphospholipid, ACL: anticardiolipin.
Table 3 Frequency of HLA-DQB1*06 in systemic lupus erythematosus (SLE) patients versus healthy controls.
HLA-DQB1*06 Control SLE patients OR 95% CI P-value Sig.
N (%) N (%)
Negative 45 (91.8) 29 (60.4) 7.23 2.22–23.6 0.000 HS
Positive 4 (8.2) 19 (39.6)
HLA, human leucocyte antigen; OR, odds ratio; 95% CI, 95% conﬁdence interval.
*Signiﬁcant P-value if <0.05, highly signiﬁcant P-value if <0.01.
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strating the strongest association [19].
Our results showed HLA-DQB1*06 to be associated with
SLE (39.6% in patients and 8.2% in controls, OR = 7.23;
95% CI = 2.22–23.6; P= 0.000). Similar results were
reported among Saudi SLE patients where the HLA-
DQB1*06 frequency was 40% (OR= 1.67; 95% CI = 1.19–
2.36; P= 0.003) [20]. A signiﬁcant increase in the frequency
of HLA-DQ6 (*0601–*0609) was found among Iranian
patients with SLE where 25 of 40 patients (62.5%) with SLE
were HLA-DQ6 positive. This was the highest frequency com-
pared to other DQB1 alleles (DQ2, DQ4, DQ5, DQ7, DQ8and DQ9) [10]. Frequencies of DQB1*0602 were also signiﬁ-
cantly increased amid Tunisians among other HLA alleles
(DRB1*1501–DQA1*0102, and DRB1*0301–DQA1*0501–
DQB1*0201) [21]. Shankarkumar et al. showed a signiﬁcant
increase in the frequency of DQB1*0601, among other alleles
in Indian patients with SLE [22]. HLA-DQB1*06 was also
present in 23% of Hungarian SLE patients [23].
The role of HLA molecules in autoimmune disease might
be related to their role in antigen presentation to T cells, in
terms of presentation of a disease-triggering self-peptide, or
altered-self-peptide. Alternatively, HLA may play a causative
role via inﬂuence on the T-cell repertoire, including T
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the associated HLA polymorphism may play no direct role,
merely acting as a marker [8,24–26].
Studies in other populations gave varying results. Vargas-
Alarcon et al. reported that the DRB1*0301 is the principal
class II allele associated with the genetic susceptibility to SLE
in Mexicans [27]. Similar results were reported in Latin
Americans with no HLA-DQB1 alleles showing a signiﬁcant
deviation from the control group [2,28]. Sirikong et al. in
2002 reported a signiﬁcant association of HLA-DRB1*1502–
DQB1*0501 haplotype was demonstrated in Thais [12]. Among
Hungarian SLE patients there was increased prevalence of the
DRB1*1501, DRB1*03 DQA1*0102, DQB1*0201, as well as
DQB1*0602 alleles [29]. Studies on European ancestry to
determine association at classical HLA genes showed associa-
tion with HLA-DRB1*03:01, HLA-DRB1*08:01, and HLA-
DQA1*01:02 [6].
The possible explanations for differences of susceptible
genetic factors between populations could be different genetic
backgrounds, contribution of gene–gene or gene–environment
interaction, and the relation between marker and causal vari-
ants. Therefore, efforts to identify ethnic-speciﬁc genetic factors
or disease causing variants are necessary for individualized
therapy for SLE in future [13].
We also explored associations of DQB1*06 alleles with SLE
phenotypes including the presence of autoantibody and clinical
manifestations of disease. We found no association with the
clinical ﬁndings or antibodies found in our patients apart from
a signiﬁcant negative association with vasculitis. Rezaieyazdi
et al. [10] also reported absence of signiﬁcant association
between DQ6 and severity of disease in their patients. Contrary
to our results Malaysians demonstrated signiﬁcant association
of DQB1*0601 with anti-Sm/RNP and with anti-dsDNA [30].
Tunisians showed no signiﬁcant association of HLA-
DQB1*06 with any of the speciﬁc antibodies in SLE [21].
In conclusion, the current work suggests that the DQB1*06
allele is a susceptibility allele in Egyptian patients with SLE
but is not related to the clinical presentation or laboratory tests
of SLE. To our knowledge this is the ﬁrst study of the fre-
quency of DQB1*06 alleles in Egyptian SLE patients.Conﬂict of interest
We have no conﬂict of interest to declare.References
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